Business Context and Reporting Period
Company: Grifols, S.A.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2016
Accounting Basis: International Financial Reporting Standards (IFRS)
Reporting Currency: Euro (EUR)
Grifols is a vertically integrated global producer of plasma derivatives, diagnostics, and hospital products. The company operates four divisions: Bioscience (79.7% of revenue), Diagnostic (16.4%), Hospital (2.4%), and Raw Materials and Others (1.5%). The company is headquartered in Spain but derives the majority of its revenue (65.8%) from the United States and Canada.
Key Financial Metrics (Year Ended Dec 31, 2016)
| Metric | 2016 (EUR millions) | 2015 (EUR millions) | Change |
|---|---|---|---|
| Net Revenue | 4,049.8 | 3,934.6 | +2.9% |
| Gross Profit | 1,912.3 | 1,931.0 | -1.0% |
| Gross Margin | 47.2% | 49.1% | -190 bps |
| Operating Result (EBIT) | 939.4 | 970.4 | -3.2% |
| Profit After Tax | 544.5 | 531.4 | +2.5% |
| EBITDA | 1,141.3 | 1,141.3 (approx) | Stable |
| Basic EPS | 0.80 | 0.78 | +2.6% |
| Cash & Equivalents | 895.0 | 1,142.5 | -21.7% |
| Total Debt (Financial Liabilities) | 4,942.1 | 4,860.2 | +1.7% |
Note: EBITDA is a non-IFRS measure reconciled in the filing. Total debt includes current and non-current financial liabilities.
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 2.9% (3.1% at constant currency). Growth was driven primarily by the Bioscience division (+6.5%), offset by a decline in the Diagnostic division (-4.0%) and a significant drop in "Raw Materials and Others" (-48.6%) due to lower royalty revenues from the Novartis acquisition.
- Margin Compression: Gross margin decreased from 49.1% to 47.2%. This was attributed to higher plasma costs (increased donor incentives and new center investments) and the decline in high-margin royalty revenue.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses rose 5.3% due to intensified sales and marketing efforts. Research and development (R&D) spending decreased 11.9% to €197.6 million.
- Finance Result: Finance costs decreased 14.1% to €233.6 million, primarily due to the termination of interest rate derivatives and favorable exchange rate variations.
- Working Capital: Inventory levels increased by €173.0 million (turnover days rose to 281) to support sales growth and new plasma collection centers. Trade receivables increased by €43.3 million.
Guidance, Outlook, and Risks
Outlook and Strategy:
- Capital Expenditures: The company is undertaking a €1.2 billion investment plan (2016–2020) to expand manufacturing capacity, particularly in the Bioscience division, and to open new plasma collection centers (targeting 225 centers by 2021).
- R&D Pipeline: Key projects include the AMBAR study for Alzheimer's disease (Albumin/IVIG), antithrombin for cardiac surgery, and fibrin glue. R&D spending is expected to range between 5% and 6% of net revenue in the near term.
- Acquisitions: Subsequent to year-end, Grifols completed the acquisition of Hologic's NAT Donor Screening Unit (Jan 2017) for $1.865 billion and acquired a 49% stake in Access Biologicals.
Key Risks and Contingencies:
- Debt Levels: The company carries substantial indebtedness (approx. €4.9 billion), which restricts flexibility and increases vulnerability to economic downturns. A significant portion of debt is variable-rate.
- Plasma Supply: Growth is dependent on access to U.S. source plasma. Disruptions in collection centers or donor pool reductions could materially impact revenue.
- Regulatory Environment: Strict FDA and EMA regulations govern manufacturing and product approval. Non-compliance could lead to shutdowns or recalls. Healthcare reform and pricing pressures (Medicaid/Medicare) pose ongoing risks to reimbursement rates.
- Product Liability: Risks associated with biological products, including potential transmission of pathogens or adverse side effects, remain a material concern.
Investor Verification Checklist
- Debt Refinancing: Verify the status of the "Existing Notes" (5.25% Senior Notes due 2022) and the terms of the "New Credit Facilities" entered into in January 2017 to fund the Hologic acquisition.
- Plasma Collection Capacity: Confirm progress toward the target of 225 FDA-approved plasma collection centers by 2021 and monitor donor recruitment trends.
- Margin Trends: Monitor the impact of rising plasma costs and donor incentives on gross margins, specifically in the Bioscience division.
- Regulatory Compliance: Review any FDA or EMA inspection reports for the Clayton, Los Angeles, and Parets facilities for potential compliance issues.
- Reimbursement Policy: Track changes in U.S. healthcare legislation (Medicare/Medicaid) and pricing negotiations that could affect the high-margin IVIG and Albumin products.